Clearside Biomedical, Inc CLSD Stock Forecast & Price Targets

The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks t account example for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. The Company is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS).

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.

Short Interest (08/31/

Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Shares of Bausch Health Companies Inc. were up 0.3% in premarket trading on Tuesday after it announced the publication of late-stage trial data for an investigational eye therapy it is developing with Clearside Biomedical… Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. The scores are based on the trading styles of Value, Growth, and Momentum.

Sometimes press release headlines and share prices don’t match up. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.

Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.

In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. The average analyst rating for CLSD stock from 5 stock analysts is „Strong Buy“. This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

What 8 Analyst Ratings Have To Say About Clearside Biomedical

As of August 31st, there was short interest totaling 263,400 shares, an increase of 20.2% from the August 15th total of 219,200 shares. Based on an average trading volume of 123,200 shares, the short-interest ratio is presently 2.1 days. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

View analysts price targets for CLSD or view top-rated stocks among Wall Street analysts. Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS.

Research & Ratings Clearside Biomedical Inc.(CLSD)

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat’s FREE daily newsletter. We’d like to share more about how we work and what drives our day-to-day business. Compare
CLSD’s historical performance
against its industry peers and the overall market.

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.

CLSD Clearside Biomedical, Inc.

Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams.

• The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.
• Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.
• Promising trial results helped trigger a short squeeze and sent the biotech’s shares soaring.
• ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

Promising trial results helped trigger a short squeeze and sent the biotech’s shares soaring. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

According to 5 stock analysts, the average 12-month stock price forecast for CLSD stock stock is $5.80, which predicts an increase of 582.35%. On average, analysts rate CLSD stock stock as a strong buy. After positive clinical trial data yesterday, a regulatory update on the company’s other trials keeps the momentum going. The technique has proven to be very useful for finding positive surprises.

5 Wall Street equities research analysts have issued „buy,“ „hold,“ and „sell“ ratings for Clearside Biomedical in the last year. The consensus among Wall Street equities research analysts is that investors should https://1investing.in/ „buy“ CLSD shares. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses.

Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. 5 brokerages have issued twelve-month price objectives for Clearside Biomedical’s shares. Their CLSD share price forecasts range from $4.00 to $8.00. On average, they expect the company’s stock price to reach $5.60 in the next twelve months. This suggests a possible upside of 558.8% from the stock’s current price.

Dow Jones Network

The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of CLSD stock can currently be purchased for approximately $0.85.

More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends. According to 5 analysts, the average rating for CLSD stock is „Strong Buy.“ The 12-month stock price forecast is $5.8, which is an increase of 582.35% from the latest price. Clearside Biomedical saw a increase in short interest during the month of August.

How has CLSD performed historically compared to the market?

And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. CLSD’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. The back of the eye is the location of many irreversible and debilitating ocular conditions, and our proprietary technology precisely administers drug at the site of disease. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries.

Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Shares of Clearside Biomedical Inc. were up 12% in midday trade Thursday in the company’s debut on the Nasdaq. Shares were trading at $7.85, above the company’s $7 issue price.